Author Affiliations: Departments of Neurology,
Pediatrics, Neurosurgery, and Human Biology, The Beirne Family Director of
Neuro-Oncology at Packard Hospital, Stanford University, Stanford, Calif (Dr
Fisher); Department of Epidemiology, Kenneth and Marjorie Kaiser Endowed Chair
in Cancer Epidemiology, School of Public Health, University of California,
Berkeley (Dr Buffler).
Brain tumor is one of the diagnoses most feared by patients, physicians,
and even oncologists. Their fear is justified. More than half of the 18 400
primary malignant brain tumors diagnosed each year in the United States are
malignant gliomas1 that not only confer high
risk for death and severe disability, but also steal what is held so highly
as the essence of human life: the mind and spirit. In this issue of JAMA, Chang et al2 use data
from the Glioma Outcomes (GO) Project to provide a “report card”
on the patterns of care in patients with newly diagnosed malignant gliomas;
unfortunately, the grades are sobering. Consequently, this is an appropriate
time to reflect on the past and current status of glioma treatment and suggest
where to go from here.
Fisher PG, Buffler PA. Malignant Gliomas in 2005: Where to GO From Here? JAMA. 2005;293(5):615–617. doi:10.1001/jama.293.5.615
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: